|
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia Clinical research trials and Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia. Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia clinical trial. Human subjects often get the best healthcare available for their Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "Z" Clinical Trials Conditions > Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia  Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
For Condition: Laryngeal Cancer,lip and oral cavity cancer,Hypopharyngeal Cancer,Oropharyngeal Cancer,Nasopharyngeal Cancer,Lung Cancer
Status: Recruiting
Sponsor(s): Barbara Ann Karmanos Cancer Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of zileuton may be an effective way to prevent lung cancer in patients who have bronchialdysplasia. PURPOSE: Randomizedphase II trial to study the effectiveness of zileuton in preventing lung cancer in patients who have bronchial dysplasia.
Details: OBJECTIVES: - Determine the efficacy of zileuton, in terms of number of sites and grade of dysplastic lesions in the bronchial epithelium, in patients with documented bronchial dysplasia. - Correlate the regression of bronchial dysplasia (number and grade) and improvement in sputum cytology with the modulation of molecular biomarkers in patients treated with this drug. - Determine the overall toxicity of this drug in these patients. - Determine the 6-month stability of the chemopreventive effect of zileuton in patients who are randomized to receive initial treatment with this drug. - Determine the 6-month natural history of bronchial dysplasia in patients who are randomized to receive initial treatment with a placebo. OUTLINE: This is a randomized, double-blind, placebo-controlled, crossover, multicenter study. Patients are stratified according to clinical site, smoking status (current vs recently quit smoker), and prior cancer (none vs lung or head and neck). All patients receive oral placebo 4 times daily for 2 weeks. Patients who exhibit sufficient compliance are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral zileuton 4 times daily for 6 months followed by oral placebo 4 times daily for an additional 6 months in the absence of disease progression or unacceptable toxicity. - Arm II: Patients receive oral placebo 4 times daily for 6 months followed by oral zileuton 4 times daily for an additional 6 months in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks. PROJECTED ACCRUAL: A total of 134 patients (67 per treatment arm) will be accrued for this study within 1-2 years.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - At high risk for dysplasia, defined by 1 of the following criteria: - Current or former smokers who have smoked at least 30 pack-years - Former smokers must be enrolled within 10 years of complete smoking cessation - Patients with curatively treated stage I non-small cell lung cancer* - Patients with curatively treated stage I or II squamous cell carcinoma of the head and neck (limited to oral cavity, pharynx, or larynx)* NOTE: *At least 12 months post-curative therapy - Histologic confirmation of mild to severe bronchial dysplasia on bronchoscopic biopsy required - Moderate or severe atypia on sputum cytology required before bronchoscopy - No evidence of malignancy by chest x-ray PATIENT CHARACTERISTICS: Age - 18 and over (for patients with prior lung or head and neck malignancy) - 40 and over (for all other patients) Performance status - SWOG 0-1 Life expectancy - Not specified Hematopoietic - WBC at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10.0 g/dL - No bleeding disorder Hepatic - Bilirubin no greater than upper limit of normal (ULN) - Liver enzymes no greater than ULN - PT/PTT no greater than ULN - No active or chronic liver disease (even if transaminases have normalized) Renal - Creatinine no greater than ULN Cardiovascular - No unstable angina - No uncontrolled heart failure Pulmonary - No significant asthma or chronic obstructive pulmonary disease requiring chronic or periodic (at least once per year) steroids for flares - No acute or chronic respiratory failure Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Willing and able to undergo serial bronchoscopic examinations - No ongoing alcohol use (i.e., at least 1 glass of wine, beer, or a mixed drink per day on a regular basis) - No other medical condition that would preclude safety during study participation - No other active or invasive malignancy within the past year except basal cell skin cancer or carcinoma in situ of the cervix - No hypersensitivity to study drug or any of its inactive ingredients PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - More than 3 months since prior corticosteroids* - No concurrent corticosteroids* - No concurrent anticancer hormonal agents NOTE: *Systemic or inhaled, including chronic administration Radiotherapy - No concurrent radiotherapy Surgery - Not specified Other - More than 3 months since prior lipoxygenase inhibitors* - More than 3 months since prior investigational agents - More than 3 months since prior nutritional supplements (except 1 daily multivitamin) - No concurrent nutritional supplements (except 1 daily multivitamin) - No other concurrent lipoxygenase inhibitors* - No other concurrent investigational agents - No concurrent warfarin, beta-blockers, or theophylline - No other concurrent antineoplastic agents - No concurrent or chronic daily use of non-steroidal anti-inflammatory agents (NSAIDS) (except cardioprotective doses of aspirin less than 100 mg/day) - Periodic use of NSAIDS allowed - Concurrent participation in a smoking cessation program (including use of bupropion or nicotine gum or patch) allowed NOTE: *Systemic or inhaled, including chronic administration
Total Enrollment:
Location and Contact Information:
Overall Study Official:
OmerKucuk, Study Chair, Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute *Recruiting*
Detroit, Michigan, 48201
United States
Recruiting Omer Kucuk 313-745-2797
Additional Information:
Study ID Numbers: CDR0000271915; WSU-093201MP4F,WSU-C-2405
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056004
Other Hypopharyngeal Cancer Studies:
1. Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx
2. Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
3. RK-0202 in Preventing Oral Mucositis in Patients Who are Undergoing Radiation Therapy for Cancer of the Mouth, Throat, or Salivary Glands
4. Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
5. Administration of EBV-Specific Cytotoxic T-Lymphocytes to Patients with EBV-Positive Cancer of the Nose and Throat
Related Studies:
Other Hypopharyngeal Cancer Clinical Trials
Other Michigan Clinical Trials
Other Detroit Clinical Trials
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
|
|
|
|
|
|
|
|
